Treatment of chronic non-infectious uveitis and scleritis

Ocular inflammations such as uveitis and scleritis can lead to significant visual impairment if not treated properly. To limit potentially sight-threatening complications, good control of the inflammation in the acute phase is necessary. Corticosteroids have been the mainstay of ocular therapies f...

詳細記述

書誌詳細
主要な著者: Daniele C. Rossi, Camillo Ribi, Yan Guex-Crosier
フォーマット: 論文
言語:English
出版事項: SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2019-03-01
シリーズ:Swiss Medical Weekly
主題:
オンライン・アクセス:https://www.smw.ch/index.php/smw/article/view/2583
その他の書誌記述
要約:Ocular inflammations such as uveitis and scleritis can lead to significant visual impairment if not treated properly. To limit potentially sight-threatening complications, good control of the inflammation in the acute phase is necessary. Corticosteroids have been the mainstay of ocular therapies for many years, but high doses of corticosteroids, which are required to maintain quiescence in severe uveitis, can be associated with many systemic and ocular complications. In order to limit steroid side-effects, classic immunosuppressant and immunobiologic agents have been widely used as steroid-sparing agents. In this review, we summarise the immunosuppressive drug therapy utilised in the treatment of ocular inflammatory diseases.
ISSN:1424-3997